Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.
about
Pseudovirions as vehicles for the delivery of siRNAOncolytic Sendai virus-based virotherapy for cancer: recent advancesA new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivoInactivated Sendai virus strain Tianjin induces apoptosis in breast cancer MCF-7 cells by promoting caspase activation and Fas/FasL expression.Systemic administration of platelets incorporating inactivated Sendai virus eradicates melanoma in miceMechanisms of Oncolysis by Paramyxovirus SendaiOncolysis by paramyxoviruses: preclinical and clinical studies.Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis.Inactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis.Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene.Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity.Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application.13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma.The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma.Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner.Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.Virosome presents multimodel cancer therapy without viral replication.Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells.IPS-1 plays a dual function to directly induce apoptosis in murine melanoma cells by inactivated Sendai virus.Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study).Fusogenic Viruses in Oncolytic Immunotherapy
P2860
Q24634231-AC9636E5-DAFE-4A56-9410-E1787186F6AAQ26825239-BF9EB646-913A-4BFE-9130-FB019DA2CAACQ33299767-5D0D7A93-696B-438F-A4BE-A31D28657C06Q34560282-A3C5BAF2-F4BB-4EBE-9711-E4BA0C302B8EQ35068459-FB670E76-9ECD-4518-A597-77D512B638AFQ35600291-8F4E324B-5284-461C-9A79-8B506A7ADB2AQ35721486-4FFD0970-EAB5-4BFF-95B6-D3D2D296D0F4Q35861933-B019EBDF-8D1A-459B-A685-3B480C6ADC7CQ35861936-DB3F14CC-B894-4CF5-8047-3D748B73EE9AQ36582852-95539128-3DE0-4BAF-B460-67C90E0DA639Q37352017-F906AD9C-87A9-41DF-89B8-8AB104A3415AQ37392634-1CF03C60-4C80-4F4D-AF17-122F09B53697Q37520497-01AA87DD-F5C7-4D4D-AE26-DE3E4953E3D0Q37780547-34FA6E50-7E8F-48BC-9E55-D5B3A02EB3F4Q38008023-B494DB2E-1C36-4C1A-9FBA-D8276E06D146Q38155377-B360552A-054D-4879-AAB6-4CBBAD3BADB0Q39248316-AC5D6F16-4AEE-4D59-9E1E-D0DD6658702EQ39477668-AB99E937-B034-4C29-805E-42FBD002CB85Q39999617-BCF41051-07ED-4283-9C79-F24D7E1FEBF2Q40204247-F24026E8-D0CB-40E5-81FF-F70ED05B39FEQ41812409-13440BAC-6ACD-4FCC-A553-EE61E286BA8CQ41930795-44CB67DA-1E9F-4F8A-95ED-77256C6F3FE4Q44068008-8DE4F510-AC58-4848-BC0F-8ABC573A4705Q45863017-89E67322-FC8E-45CD-8C57-49DBBEA7AF7CQ45887671-0BBF01FD-2A8E-4A10-B34C-1EF9FABC432FQ55085319-6854110C-1918-4BB2-BD67-B3DD8DDD3A55Q55366271-75F981A2-6451-4D5C-9744-FD10E62A338EQ56971929-C73C5C2A-A308-47EF-B7D0-CC7EFAEF3FCB
P2860
Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Intratumoral injection of inac ...... d systemic NK cell activation.
@en
Intratumoral injection of inac ...... d systemic NK cell activation.
@nl
type
label
Intratumoral injection of inac ...... d systemic NK cell activation.
@en
Intratumoral injection of inac ...... d systemic NK cell activation.
@nl
prefLabel
Intratumoral injection of inac ...... d systemic NK cell activation.
@en
Intratumoral injection of inac ...... d systemic NK cell activation.
@nl
P2093
P2860
P1476
Intratumoral injection of inac ...... d systemic NK cell activation.
@en
P2093
Atsuko Fujihara
Masayuki Kurooka
Tsuneharu Miki
Yasufumi Kaneda
P2860
P2888
P356
10.1007/S00262-007-0351-Y
P577
2007-06-30T00:00:00Z
P6179
1035264410